Bitter Pills:Medicines & The Third World Poor | Page 4

ACKNOWLEDGEMENTS
This book would never have materialised without the invaluable help of experts, colleagues and friends.
I am particularly grateful to my colleagues David Bull and Adrian Moves for their unstinting advice
and encouragement and for their sense of humour. Special thanks go to David Newell, Julu, Niaz,
Saidur and others at OXFAM's Dacca office and to medical advisers, Dr. Tony Klouda and Dr. Tim
Lusty. Many colleagues have helped, especially in the Secretarial Services Department, but one in
particular has laboured for many hours producing immaculate typescript - my special thanks to Betty
Hawkins. Thanks also to Alan Bell for producing the index.
I wish to thank the OXFAM trustees and members of the Field Committees who devoted time and
effort to helping with improvements to the early drafts, particularly Dr. William Cutting, Dr. Chris
Manning and Michael Rowntree, Chairman of the editorial panel.
For their expert advice and for the many demands made on their time, 1 especially wish to thank
Dr. Humayun Hye, formerly Director of Drug Administration in Bangladesh, Professor Mike Rawlins,
Head of the Department of Clinical Pharmacology at the University of Newcastle and Dr. John Yudkin,
Consultant/Senior Lecturer in General Medicine, Whittington Hospital, London.
1 am grateful to the following for their contributions to our research and to some also for their helpful
comments on the early drafts:
Selim Ahmed (Voluntary Health Services Society, Bangladesh); Dr. Raj Anand (Bombay);
Dr. F. S. Antezana (WHO, Geneva); Dr. K.M .S. Aziz (International Centre for Diarrhoeal Disease
Research, Bangladesh); Dr. K. Balasubramanian (UNCTAD, Geneva); Sharon Banoff and Ritchie
Cogan (BBC, London); Dr. Carol Barker (Nuffield Centre for Health Services Studies, Leeds); David
Beynon (Pharmaceutical Supply Officer, Madang Department of Health, Papua New Guinea); Dorit
Braun; Dr. Pascale Brudon (Geneva); Dr. James Burton and Bill Davies (ECHO, Ewell); Sue Cavanna
(Sichili Hospital, Zambia); Dr. Zafrullah Chowdhury (Gonoshasthaya Kendra, Bangladesh); Ralph
Cox (DHSS, London); Professor P. F. D'Arcy (Head, Department of Pharmacy, The Queen's
University of Belfast); Bharat Dogra (Delhi); Anne Ferguson (Michigan State University, USA); Foo
Gaik Sim (Head, Research and Information, International Organisation of Consumer Unions, Penang);
Doris Frizel (Bo Hospital, Sierra Leone); Dr. Jaime Galvez-Tan (Philippines); Dr. L. G. Goodwin
(Director of Science, Zoological Society of London); Dr. C. E. Gordon-Smith (The Dean, London
School of Hygiene and Tropical Medicine); Bob Grose (British Organization for Community
Development, Yemen Arab Republic); Dr. Hassani (Director, Norwegian SCF Clinic, Ibb, Yemen
Arab Republic); Dr. Andrew Herxheimer (Dept. of Pharmacy, Charing Cross Hospital Medical School,
London); Dr. Ann Hoskins and sister Raymi volunteers (British Organisation for Community
Development, Yemen Arab Republic); Professor Nurul Islam (Director, Institute of Postgraduate
Medicine and Research); Dr. Vida Jelling (ex-VSO); Dr. Juel-Jensen (Oxford University Medical
Officer); Dr. Sultana Khanum (SCF Children's Nutrition Unit, Bangladesh); Dr. Sanjaya Lall (Oxford
University Institute of Economics and Statistics); Dr. Jane Mackay (ex-VSO); Charles Medawar (Social
Audit Ltd., London); Ross Mountain (UNNGLS, Geneva); Linda Nicholls (pharmacist); Professor
Georges Peters (Institut du Pharmacologie, Universite de Lausanne); Dr. Ahmed Rhazoui (UNCTC,
New York); Dr. B. Sankaran (WHO, Geneva); Dr. Satoto (Indonesia); Dr. Martin Schweiger; Dr.
Mira Shiva and S. Srinivasan (VHAI, Delhi); Dr. Milton Silverman and Mia Lydecker (University
of California); Dr. Pawan Sureka (Bombay); Ken Temple (ODA, London); Dr. Wanandi (WHO,
Geneva); David Werner (Hesperian Foundation, California); the pharmacists at Westlake Ltd.
(Banbury Road, Oxford); and Stephen de Winter and colleagues (Belbo Film Productions, Netherlands).
I would like to thank all those representatives of the pharmaceutical industry who have provided
help and information, particularly David Taylor (Deputy Director, Office of Health Economics,
London); representatives of the Association of British Pharmaceutical Industries and the International
Federation of Pharmaceutical Manufacturers Associations; and executives of Beecham, Boots, CibaGeigy, Cyanamid, Fisons, Glaxo, Hoechst, ICI, May & Baker UK, E. Merck, Merck Sharp & Dohme,
Organon, Pfizer, Rivopharm, Roche, Sandoz, G. D. Searle, Squibb, Upjohn and The Wellcome
Foundation.
Finally, special thanks to Helen and Chris for encouragement when I needed it most.